Nuclear Medicine

Delegates express concerns that PPE doesn't always cover women, who are more at risk of exposure

Odds of undetectable PSA at 48 weeks doubled with addition of Pluvicto

Small study suggests large benefit for Lu-177 dotatate in intracranial disease

Findings support PSMA PET in the preoperative workflow of intermediate- and high-risk tumors

But it may be able to deliver net carbon benefits, at least in radiology

Median OS of 15.5 months, PFS of 7.9 months with Ac-225-PSMA in heavily treated patients

Study shows twice as many locally advanced patients upstaged with PET-CT vs conventional staging

Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET

All but one patient had a PSA decline after a fractionated dose of 225Ac-J591

Randomized study finds no meaningful difference in events of abnormalities between groups

Small increase in median PFS when combined with second-line chemotherapy

No overall risk increase in large meta-analysis, but higher risk seen for thyroid cancer

Increase in negative predictive value and improved sensitivity versus MRI alone

The debate continues in two dueling articles